Article

Recommendations for the administration of influenza vaccine in children allergic to egg.

Southampton University Hospitals NHS Trust, Southampton.
BMJ (online) (Impact Factor: 16.38). 09/2009; 339:b3680. DOI: 10.1136/bmj.b3680
Source: PubMed
0 Followers
 · 
220 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: In egg-allergic individuals, vaccines measles-mumps-rubella (MMR), influenza, yellow fever, rabies and tick-borne encephalitis scare patients but also doctors who too often in this population indicates cons. Legal notices accompanying these vaccines reinforce the belief of doctors about the danger of these vaccines in egg-allergic patients. Yet allergic response to these vaccines are exceptional among egg-allergics. The few reactions are probably not related to egg-allergy. Current vaccines contain, for most, trace of egg protein or do not contain (MMR, Rabies). Since long it is shown that the ovalbumin content of most current vaccines do not trigger a reaction in allergy sufferers. Skin tests to vaccines, previously done, have not shown interest, for MMR and influenza vaccines. It persists only uncertainty for vaccination against yellow fever and tick-borne encephalitis. A change of legal notices for MMR and influenza is required. A campaign to inform doctors practicing vaccinations is urgently needed to avoid unnecessary health care costs.
    Revue Française d Allergologie 04/2011; 51(3):238-242. DOI:10.1016/j.reval.2010.12.005 · 0.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Modern cell-culture production techniques and the use of adjuvants helps to ensure that the global demand for pandemic influenza vaccine can be met. This study aimed to assess the immunogenicty and safety profiles of various cell-culture-derived A/H1N1 pandemic vaccine formulations in healthy adult and elderly subjects. Adult (18-60 years) subjects (n=544) received vaccine either containing 3.75 μg of antigen with half the standard dose of MF59 (Novartis Vaccines and Diagnostics) adjuvant, 7.5 μg antigen with a full dose of MF59, or a non-adjuvanted vaccine containing 15 μg of antigen. Elderly (≥ 61 years) subjects (n=268) received either the 3.75 μg or 7.5 μg adjuvanted formulations. Two priming vaccine doses were administered 3 weeks apart, followed by a single booster dose of seasonal influenza vaccine 1 year later. Immunogenicity was assessed 3 weeks after each vaccination. The safety profile of each formulation was evaluated throughout the study. A single primary dose of each A/H1N1 vaccine formulation was sufficient to meet all three European (CHMP) licensure criteria for pandemic influenza vaccines in adult subjects. Two licensure criteria were met after one vaccine dose in elderly subjects; two primary doses were required to meet all three criteria in this age group. The highest antibody titres were observed in response to the 7.5 μg vaccine containing a full dose of MF59 adjuvant. All subjects rapidly generated seroprotective antibody titres in response to booster vaccination. This study identified one 3.75 μg vaccine dose containing half the standard dose of MF59 adjuvant as optimal for adults, two doses were optimal for elderly subjects. The antigen-sparing properties of MF59, and rapid, modern, cell-culture production techniques represent significant steps towards meeting the global demand for influenza vaccine.
    Vaccine 05/2012; 30(32):4820-7. DOI:10.1016/j.vaccine.2012.05.013 · 3.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The highly pathogenic avian influenza (HPAI) H5N1 virus has become highly enzootic since 2003 and has dynamically evolved to undergo substantial evolution. Clades 2.3.2.1 and 2.3.4 have become the most dominant lineage in recent years, and H5N8 avian influenza outbreaks have been reported Asia. The current approach to generate influenza virus vaccines uses embryonated chicken eggs for large-scale production, although such vaccines have been poorly immunogenic to heterologous virus challenge. In the current study, virus-like particles (VLP) based on A/meerkat/Shanghai/SH-1/2012 (clade 2.3.2.1) and comprising hemagglutinin (HA), neuraminidase (NA), and matrix (M1) were produced using a baculovirus expression system to develop effective protection for different H5 HPAI clade challenges. Mice immunized with VLP demonstrated stronger humoral and cellular immune responses than mice immunized with whole influenza virus (WIV), with 20-fold higher IgG antibody titers against A/meerkat/Shanghai/SH-1/2012 after boost. Notably, the WIV vaccine group showed partial protection (80% survival) to homologous challenge, little protection (40% survival) to heterologous challenge, and 20% survival to H5N8 challenge, whereas all mice in the VLP+CFA group survived. These results provide insight for the development of effective prophylactic vaccines based on VLPs with cross-clade protection for the control of current H5 HPAI outbreaks in humans. Copyright © 2015. Published by Elsevier B.V.
    Virus Research 01/2015; 200. DOI:10.1016/j.virusres.2015.01.007 · 2.83 Impact Factor

Full-text (2 Sources)

Download
102 Downloads
Available from
May 22, 2014